Connecticut is currently home to 1265 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia
NCT05345561
Recruiting
A prospective, non-interventional, natural history study to assess the occurrence of higher FNAIT risk across a broad population of different racial and ethnic characteristics and the occurrence of HPA-1a alloimmunization in these women.
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: Fetal and Neonatal Alloimmune Thrombocytopenia
Register for Updates
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease Mediated Proteinuric Kidney Disease
NCT05312879
Recruiting
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Gender:
All
Ages:
Between 10 years and 65 years
Trial Updated:
04/22/2024
Locations: Greater Hartford Nephrology, Bloomfield, Connecticut
Conditions: Proteinuric Kidney Disease
Register for Updates
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
NCT05135286
Recruiting
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
Gender:
All
Ages:
Between 45 years and 80 years
Trial Updated:
04/22/2024
Locations: Visus Therapeutics Investigative Site, Danbury, Connecticut
Conditions: Presbyopia
Register for Updates
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
NCT05076175
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod will be administered orally to pediatric participants with moderate to severe active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
04/22/2024
Locations: Local Institution - 0007, Hartford, Connecticut
Conditions: Colitis, Ulcerative
Register for Updates
Digoxin In Treatment of Alcohol Associated Hepatitis
NCT05014087
Recruiting
Prospective, single center, open label, randomized controlled trial to determine the feasibility of conducting a future study with respect to patient recruitment, digoxin administration and dose adjustment. The study intervention will be intravenous digoxin (renal-based dosing for maximum of 28 days) versus no digoxin in an open-label 1:1 randomized allocation of patients with severe acute alcohol associated hepatitis.
Gender:
All
Ages:
Between 21 years and 70 years
Trial Updated:
04/22/2024
Locations: Yale New Haven Hospital, Yale School of Medicine, New Haven, Connecticut
Conditions: Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury, Alcohol-Induced Disorders, Steatohepatitis Caused by Ingestible Alcohol
Register for Updates
STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
NCT04878432
Recruiting
Main objective of this study is to describe and evaluate safety and efficacy of MBG453 (sabatolimab) in combination with FDA approved HMAs of investigator's choice (IV Decitabine or Azacitidine /SC Azacitidine /Oral Decitabine (cedazuridine combination (INQOVI))
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
04/22/2024
Locations: Yale University School Of Medicine ., New Haven, Connecticut
Conditions: Myelodysplastic Syndrome (MDS)
Register for Updates
Lead EvaluAtion for Defibrillation and Reliability (LEADR) / Lead Evaluation for Defibrillation and Reliability in Left Bundle Branch Area Pacing (LEADR LBBAP)
NCT04863664
Recruiting
The LEADR study is designed to assess the safety and efficacy of the Next Generation ICD lead. The LEADR LBBAP study is being conducted under the existing US FDA Investigational Device Exemption (IDE) for the Next Generation ICD Lead and is designed to confirm the safety and defibrillation efficacy of the Next Generation ICD Lead when placed in the LBBAP location in ICD and LOT-CRT patient population.
Gender:
All
Ages:
12 years and above
Trial Updated:
04/22/2024
Locations: LEADR: Hartford Hospital, Hartford, Connecticut
Conditions: Tachyarrhythmia
Register for Updates
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
NCT04165772
Recruiting
The purpose of this study is to find out whether the study drug, TSR-042, followed by standard chemoradiotherapy (the chemotherapy drug capecitabine + radiation therapy) and standard surgery is an effective treatment for advanced dMMR solid tumors. The study will also look at the safety of the study drug.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: Hartford Healthcare (Data Collection), Hartford, Connecticut
Conditions: Rectal Adenocarcinoma, Clinical Stage: Stage II (T3-4, N-), Stage III (Any T, N+), Solid Tumor, Solid Tumor, Adult
Register for Updates
Intranasal Insulin for Posttraumatic Stress Disorder
NCT04044534
Recruiting
To evaluate if intranasal insulin is effective in reducing PTSD symptoms.
Gender:
All
Ages:
Between 21 years and 65 years
Trial Updated:
04/22/2024
Locations: VA Connecticut Healthcare System, West Haven, Connecticut
Conditions: PTSD
Register for Updates
Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast
NCT03789162
Recruiting
The primary objective of this study is to collect de-identified, clinically-characterized stool and whole blood specimens for use in developing and evaluating the performance of new biomarker assays for the detection of colorectal cancer (CRC).
Gender:
All
Ages:
40 years and above
Trial Updated:
04/22/2024
Locations: Gastroenterology Associates of Fairfield County, P.C., Fairfield, Connecticut
Conditions: Colorectal Cancer
Register for Updates
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
NCT03547973
Recruiting
The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut
Conditions: Metastatic Urothelial Cancer
Register for Updates
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
NCT02854033
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's diseas... Read More
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
04/22/2024
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Register for Updates